SH3PXD2B and hepatocellular carcinoma: More importantly, higher levels of SH3PXD2B expression were associated significantly with shorter OS and RFS periods than those with lower SH3PXD2B expression in HCC patients in the TCGA database and patients we collected in our hospital (all P < 0.05, Fig. 2c–f).